General Information of Drug (ID: DM1JOZN)

Drug Name
PMID27998201-Compound-9 Drug Info
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Patented [1]
Cross-matching ID
PubChem CID
78108715
TTD Drug ID
DM1JOZN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Preclinical Drug(s)
Drug(s) Targeting Cathepsin K (CTSK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Odanacatib DM1EO3G Osteoporosis FB83.0 Phase 3 [2]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [3]
VEL-0230 DMDSC63 Rheumatoid arthritis FA20 Phase 1 [4]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [1]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [1]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [5]
PMID27998201-Compound-15 DMOB8LU Pain MG30-MG3Z Patented [1]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R Pain MG30-MG3Z Patented [1]
PMID27998201-Compound-8 DMZK0SY N. A. N. A. Patented [1]
PMID27998201-Compound-10 DMVXTIL Osteoporosis FB83.0 Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin L (CTSL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KGP94 DM2NZ6K Coagulation defect 3B10.0 Clinical trial [6]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [1]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [1]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [5]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [1]
Phenylalanine derivative 1 DMVYP8K Glioma 2A00.0 Patented [1]
PMID27998201-Compound-7 DMU4QYR Abdominal aortic aneurysm BD50.4 Patented [1]
PMID27998201-Compound-6 DM0LGTY N. A. N. A. Patented [1]
PMID27998201-Compound-1 DM5QH4C Coronavirus infection 1D92 Patented [1]
PMID27998201-Compound-19 DM67RMX Solid tumour/cancer 2A00-2F9Z Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin B (CTSB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [1]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [1]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [1]
PMID27998201-Compound-11 DMTV5NU Metastatic cancer 2D50-2E2Z Patented [1]
PMID27998201-Compound-2 DMMAE3C Alzheimer disease 8A20 Patented [1]
PMID27998201-Compound-22 DMS9QA7 Alzheimer disease 8A20 Patented [1]
PMID27998201-Compound-13 DMZHIM8 Hepatic fibrosis DB93.0 Patented [1]
Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 DMZ4B3W Cerebral ischemia 8B11 Patented [1]
PMID27998201-Compound-24 DM25BNZ Glioma 2A00.0 Patented [1]
L-006235-1 DMMEH12 Osteoarthritis FA00-FA05 Preclinical [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin S (CTSS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7625 DMDGPKS Autoimmune disease 4A40-4A45 Phase 2 [8]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [3]
VBY- 891 DMTKPH4 Autoimmune diabetes 5A10 Phase 1 [9]
VBY- 036 DMULRYC Neuropathic pain 8E43.0 Phase 1 [10]
VBY-129 DM4YIWK Autoimmune diabetes 5A10 Phase 1 [11]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [1]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [1]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [5]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [1]
Phenylalanine derivative 1 DMVYP8K Glioma 2A00.0 Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin B (CTSB) TTF2LRI CATB_HUMAN Inhibitor [1]
Cathepsin K (CTSK) TTDZN01 CATK_HUMAN Inhibitor [1]
Cathepsin L (CTSL) TT36ETB CATL1_HUMAN Inhibitor [1]
Cathepsin S (CTSS) TTUMQVO CATS_HUMAN Inhibitor [1]

References

1 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
2 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
3 From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
4 Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
5 An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
6 Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
7 Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
10 Clinical pipeline report, company report or official report of ViroBay.
11 Clinical pipeline report, company report or official report of ViroBay.